A phase 3 study of JHL1101, a Rituximab biosimilar to treat rheumatoid arthritis in chinese population.
Phase of Trial: Phase III
Latest Information Update: 05 Feb 2018
Price : $35 *
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 05 Feb 2018 New trial record
- 01 Feb 2018 According to a JHL Biotech media release, company plans to initiate this study in 2018.